ONLINE SUPPLEMENTAL DATA

Supplemental Table 1. Patient characteristics across the two groups

	DAPT from day 1, without interruptions (n=50)	DAPT not initiated at day 1 or discontinued thereafter (n=22)	P value
Age (yr)(median)(IQR)	61 (55-70)	66 (56-72)	0.479
Male sex (n)(%)	37 (74.0%)	16 (72.7%)	1.000
Hypertension (n)(%)	30 (60.0%)	12 (54.5%)	0.796
Dyslipidemia (n)(%)	29 (58.0%)	9 (40.9%)	0.208
Diabetes (n)(%)	6 (12.0%)	3 (13.6%)	1.000
Atrial fibrillation (n)(%)	3 (6.0%)	0 (0 %)	0.548
Smoking (n)(%)	26 (52.0%)	8 (36.3%)	0.306
Baseline NIHSS (median)(IQR)	11 (4.2-14)	13 (7-17.7)	0.112
Symptom onset to femoral puncture (min)(median)(IQR)	215 (177-268)	263 (217-336)	**0.038**
IV thrombolysis (n)(%)	21 (42.0%)	10 (45.4%)	0.801
Initial DWI ASPECTS score	8 (7.2-9)	7 (6-8)	**0.002**
Initial DWI APECTS ≤ 5 (n)(%)	1 (2.0%)	4 (18.1%)	**0.028**
Proximal lesion (n)(%)			
Occlusion	35 (70.0%)	19 (86.3%)	0.236
Stenosis	15 (30.0%)	3 (13.6%)	
Etiology of proximal lesion (n)(%)			
Atheroma	37 (74.0%)	20 (90.9%)	
Dissection	12 (24.0%)	2 (9.1%)	0.254
Web	1 (2.0%)	0 (0%)	
Distal occlusion site (n)(%)			
Terminal ICA	9 (18.0%)	7 (31.8%)	
MCA M1	17 (34.0%)	11 (50.0%)	0.108
MCA M2	21 (42.2%)	3 (13.6%)	
MCA M3/M4	3 (6.0%)	1 (4.5%)	
Treatment approach (n)(%)			
Antegrade approach (neck first)	42 (84.0%)	19 (86.3%)	1.000
Retrograde approach (head first)	8 (16.0%)	3 (13.6%)	
Type of carotid stent (n)(%)			
Wallstent	45 (90.0%)	22 (100%)	
Wallstent + Casper	4 (8.0%)	0 (0%)	0.306
Casper	1 (2.0%)	0 (0%)	
Treatment for distal occlusion (n)(%)			
Stent retriever	21 (42.0%)	6 (27.2%)	
ADAPT technique	11 (22.0%)	11 (50.0%)	0.092
Distal aspiration and stent retriever	10 (20.0%)	4 (18.1%)	
None	8 (16.0%)	1 (4.5%)	
Angiographic outcome			
TICI 2b-3	49 (98.0%)	22 (100.0%)	1.000
TICI 2c-3	35 (70.0%)	17 (77.2%)	0.581
TICI 3	23 (46.0%)	10 (45.4%)	1.000
Peri-procedural antiplatelet treatment			
Aspirin	18 (36.0%)	8 (36.3%)	
Aspirin + clopidogrel	28 (56.0%)	14 (63.6%)	0.384
Aspirin + clopidogrel + GPIIb/IIIa	4 (8.0%)	0 (0%)	
Imaging outcome (n)(%)			
Total hemorrhagic transformation	12 (24.0%)	17 (77.2%)	**<0.001**
Symptomatic ICH	0 (0%)	3 (13.6%)	**0.025**
Clinical outcome at discharge			
Modified Rankin score (median) (IQR)	1 (0.2-2)	4 (2-5)	**<0.001**
Modified Rankin score ≤ 2 (n/N) (%)	41 (82.0%)	7 (31.8%)	**<0.001**
In hospital mortality	0 (0%)	0 (0%)	1.000
Duration of stent patency follow-up (days)(median)(IQR)	105 (33-144)	57 (35-125)	0.417
Stent occlusion beyond day 1 (n) (%)	1 (2.0%)	0 (0%)	1.000

IQR – interquartile range; GPIIb/IIIa– glycoprotein IIb/IIIa inhibitors